2026-08-10 · BOTH · TopGLP1Providers Data Desk
Switching providers without a bad month
Changing GLP-1 programs is straightforward if you respect one fact: the prescription does not transfer — it restarts. The destination program runs its own intake, its own prescriber writes a new patient-specific order, and its own pharmacy fills it. Done in the right order, a switch costs one overlapping shipment and zero missed weeks; done in the wrong order — cancel first, apply second — it costs a gap, and gaps in a titrated medication are exactly what your prescriber would tell you to avoid.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The sequence, in full. (1) Qualify the destination before touching the origin. Confirm in writing that it serves your state, quotes your current dose — not the starter — at a stated all-in price, and can say which pharmacy fills it. A destination that stumbles on any of the three has failed the audition at zero cost. (2) Complete intake and get the approval. Only a prescriber’s approval, not a marketing email, means medication is coming. (3) Time the overlap. Order the first destination shipment while at least ten days of origin supply remain; cold-chain shipping windows run two to seven business days and slip. (4) Cancel the origin per its published terms — the database quotes each program’s language, which ranges from “cancel anytime online” to conspicuous silence — and screenshot the confirmation, because “cancelled but still charging” is the single most common billing complaint in this category. (5) Audit the next two statements for the membership that outlived the medication.
The prepaid-balance problem. If you hold an unused prepaid term, the refund clause you did or did not read at signup is now the whole negotiation. Prorated refunds exist at some programs, forfeiture at others, and silence at too many; ask in writing, cite the published terms, and if the amount justifies it, dispute through your card issuer with the documentation trail the screenshots built. This is also the place to restate the standing rule that prevents the problem: prepay only after a program has earned months of monthly billing, and never past the horizon you would bet on at even odds — the full argument is in the prepaid mechanics guide.
Switching lanes, not just logos. Compounded-to-brand is the increasingly common move as the gap narrows ($234/month on tirzepatide at maintenance): the destination is LillyDirect↗ or NovoCare↗ plus any prescriber, the same overlap rules apply, and the dose maps one-to-one since compounded programs dose against the same ladder. Brand-to-compounded runs the same sequence in reverse with one addition — the documented clinical-need conversation that lawful 503A compounding now requires. Molecule switches (semaglutide ↔ tirzepatide) are a different animal entirely: they are clinical decisions with their own titration restarts, made with a prescriber first and priced second — the cost half is here when you get to it. For any switch, the calculator prices the candidates at your horizon, and each provider page’s record — cancellation language, watch-outs, evidence flags — is the due diligence the sequence above assumes you have read.
Logistics guidance only; medication changes, pauses, and overlaps are clinical questions for your prescriber.